NCT03807739View on ClinicalTrials.gov

A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

May 30, 2019

Study Completion Date

May 30, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

GDC-0134 F09 Formulation

Participants will receive a single oral dose of GDC-0134 reference capsule F09.

DRUG

GDC-0134 F15 Formulation

Participants will receive a single oral dose of GDC-0134 prototype capsule F15.

DRUG

GDC-0134 F16 Formulation

Participants will receive a single oral dose of GDC-0134 prototype capsule F16.

Trial Locations (2)

32117

Covance Research Unit - Daytona, Daytona Beach

75247

Covance Research Unit - Dallas, Dallas

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY